Boehringer Ingelheim Korea obtained additional indications of new oral anticoagulants (NOAC) and developed antidote

Boehringer Ingelheim Korea obtained additional indications of new oral anticoagulants (NOAC) 'Pradaxa (dabigatran)' including 'treatment and reducing recurrence risk of acute deep vein thrombosis (DVT) and pulmonary embolism (PE)'.

In addition to expanding indication, Boehringer Ingelheim was recognized of innovative treatment 'idarucizumab' from U.S. FDA, and they are trying hard to different...